Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
North Coast Cancer Care, Incorporated
mi
from
Sandusky, OH
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
North Coast Cancer Care, Incorporated
mi
from
Sandusky, OH
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Flower Hospital Cancer Center
mi
from
Sylvania, OH
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Flower Hospital Cancer Center
mi
from
Sylvania, OH
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Mercy Hospital of Tiffin
mi
from
Tiffin, OH
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Mercy Hospital of Tiffin
mi
from
Tiffin, OH
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Toledo Hospital
mi
from
Toledo, OH
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Toledo Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
St. Vincent Mercy Medical Center
mi
from
Toledo, OH
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
St. Vincent Mercy Medical Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Medical University of Ohio Cancer Center
mi
from
Toledo, OH
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Medical University of Ohio Cancer Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
CCOP - Toledo Community Hospital
mi
from
Toledo, OH
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
CCOP - Toledo Community Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Toledo Clinic, Incorporated - Main Clinic
mi
from
Toledo, OH
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Toledo Clinic, Incorporated - Main Clinic
mi
from
Toledo, OH
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
UVMC Cancer Care Center at Upper Valley Medical Center
mi
from
Troy, OH
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
UVMC Cancer Care Center at Upper Valley Medical Center
mi
from
Troy, OH
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Fulton County Health Center
mi
from
Wauseon, OH
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Fulton County Health Center
mi
from
Wauseon, OH
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
United States Air Force Medical Center - Wright-Patterson
mi
from
Wright-Patterson Afb, OH
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
United States Air Force Medical Center - Wright-Patterson
mi
from
Wright-Patterson Afb, OH
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
mi
from
Xenia, OH
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
mi
from
Xenia, OH
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Natalie Warren Bryant Cancer Center at St. Francis Hospital
mi
from
Tulsa, OK
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Natalie Warren Bryant Cancer Center at St. Francis Hospital
mi
from
Tulsa, OK
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Geisinger Medical Center
mi
from
Danville, PA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Allegheny Cancer Center at Allegheny General Hospital
mi
from
Pittsburgh, PA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Allegheny Cancer Center at Allegheny General Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Geisinger Medical Group - Scenery Park
mi
from
State College, PA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Geisinger Medical Group - Scenery Park
mi
from
State College, PA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Avera Cancer Institute
mi
from
Sioux Falls, SD
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Avera Cancer Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Sioux Valley Hospital at University of South Dakota Medical Center
mi
from
Sioux Falls, SD
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Sioux Valley Hospital at University of South Dakota Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
Central Wisconsin Cancer Program at Agnesian HealthCare
mi
from
Fond du Lac, WI
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Central Wisconsin Cancer Program at Agnesian HealthCare
mi
from
Fond du Lac, WI
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Rush-Copley Cancer Care Center
mi
from
Aurora, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Rush-Copley Cancer Care Center
mi
from
Aurora, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
St. Joseph Medical Center
mi
from
Bloomington, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
St. Joseph Medical Center
mi
from
Bloomington, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Graham Hospital
mi
from
Canton, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Graham Hospital
mi
from
Canton, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Memorial Hospital
mi
from
Carthage, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Memorial Hospital
mi
from
Carthage, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Eureka Community Hospital
mi
from
Eureka, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Eureka Community Hospital
mi
from
Eureka, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Galesburg Clinic, PC
mi
from
Galesburg, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Galesburg Clinic, PC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Mason District Hospital
mi
from
Havana, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Mason District Hospital
mi
from
Havana, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Hopedale Medical Complex
mi
from
Hopedale, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Hopedale Medical Complex
mi
from
Hopedale, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Joliet Oncology-Hematology Associates, Limited - West
mi
from
Joliet, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Joliet Oncology-Hematology Associates, Limited - West
mi
from
Joliet, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Kewanee Hospital
mi
from
Kewanee, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Kewanee Hospital
mi
from
Kewanee, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
McDonough District Hospital
mi
from
Macomb, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
McDonough District Hospital
mi
from
Macomb, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
BroMenn Regional Medical Center
mi
from
Normal, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
BroMenn Regional Medical Center
mi
from
Normal, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Community Cancer Center
mi
from
Normal, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Community Cancer Center
mi
from
Normal, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
OSF Saint Elizabeth Medical Center
mi
from
Ottawa, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
OSF Saint Elizabeth Medical Center
mi
from
Ottawa, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Oncology Hematology Associates of Central Illinois, PC - Ottawa
mi
from
Ottawa, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Oncology Hematology Associates of Central Illinois, PC - Ottawa
mi
from
Ottawa, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Cancer Treatment Center at Pekin Hospital
mi
from
Pekin, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Cancer Treatment Center at Pekin Hospital
mi
from
Pekin, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Proctor Hospital
mi
from
Peoria, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Proctor Hospital
mi
from
Peoria, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Oncology Hematology Associates of Central Illinois, PC - Peoria
mi
from
Peoria, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Oncology Hematology Associates of Central Illinois, PC - Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
OSF St. Francis Medical Center
mi
from
Peoria, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
OSF St. Francis Medical Center
mi
from
Peoria, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Illinois Valley Community Hospital
mi
from
Peru, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Illinois Valley Community Hospital
mi
from
Peru, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
St. Margaret's Hospital
mi
from
Spring Valley, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
St. Margaret's Hospital
mi
from
Spring Valley, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Carle Cancer Center at Carle Foundation Hospital
mi
from
Urbana, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Carle Cancer Center at Carle Foundation Hospital
mi
from
Urbana, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
St. Francis Hospital and Health Centers - Beech Grove Campus
mi
from
Beech Grove, IN
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
St. Francis Hospital and Health Centers - Beech Grove Campus
mi
from
Beech Grove, IN
Click here to add this to my saved trials